Source 1primary paper2025MED
Toolkit/CAR-T therapy
CAR-T therapy
Also known as: CAR-T, CAR T cell therapy, Chimeric antigen receptor T cell therapy
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Chimeric antigen receptor (CAR) T cell (CAR-T) therapy is a form of adoptive immunotherapy based on the genetic engineering of T lymphocytes.
Usefulness & Problems
Why this is useful
CAR-T therapy engineers T lymphocytes to express chimeric antigen receptors that bind target cell-surface antigens. The abstract states this enables precise and efficient immune responses.; adoptive immunotherapy; targeting respiratory diseases; direct recognition of target cell surface antigens
Source:
CAR-T therapy engineers T lymphocytes to express chimeric antigen receptors that bind target cell-surface antigens. The abstract states this enables precise and efficient immune responses.
Source:
adoptive immunotherapy
Source:
targeting respiratory diseases
Source:
direct recognition of target cell surface antigens
Problem solved
It addresses the need for antigen-directed immune attack while circumventing major histocompatibility complex-restricted antigen presentation. The review frames this as a basis for expanding therapy into respiratory diseases.; enables direct binding to target cell-specific surface antigens without requiring major histocompatibility complex-restricted antigen presentation
Source:
It addresses the need for antigen-directed immune attack while circumventing major histocompatibility complex-restricted antigen presentation. The review frames this as a basis for expanding therapy into respiratory diseases.
Source:
enables direct binding to target cell-specific surface antigens without requiring major histocompatibility complex-restricted antigen presentation
Problem links
enables direct binding to target cell-specific surface antigens without requiring major histocompatibility complex-restricted antigen presentation
LiteratureIt addresses the need for antigen-directed immune attack while circumventing major histocompatibility complex-restricted antigen presentation. The review frames this as a basis for expanding therapy into respiratory diseases.
Source:
It addresses the need for antigen-directed immune attack while circumventing major histocompatibility complex-restricted antigen presentation. The review frames this as a basis for expanding therapy into respiratory diseases.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Mechanisms
adoptive cellular immunotherapydirect antigen binding by chimeric antigen receptorsgenetic engineering of t lymphocytesmajor histocompatibility complex-independent target recognitionTranslation ControlTechniques
No technique tags yet.
Target processes
manufacturingtranslationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: multi component delivery burdenoperating role: regulatorswitch architecture: multi component
The approach requires genetically engineered T lymphocytes and a targetable surface antigen on diseased cells. The abstract also implies substantial manufacturing and logistics support are needed.; requires genetic engineering of T lymphocytes; depends on suitable target cell surface antigens
The abstract states that CAR-T translation in respiratory diseases remains limited by antigen heterogeneity, immunosuppressive solid-tumor microenvironments, and manufacturing/logistical barriers.; limited availability of tumor-specific antigens; heterogeneous expression of target antigens; immunosuppressive microenvironment of solid tumors can impair CAR-T functionality; manufacturing and logistical hurdles impede clinical translation
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
CAR-T therapy is being investigated for respiratory malignancies, severe asthma, infectious diseases, idiopathic pulmonary fibrosis, and autoimmune disorders with pulmonary involvement.
With ongoing advancements, CAR-T therapy holds promise as a versatile and effective treatment for otherwise refractory respiratory diseases.
CAR-T therapy is an adoptive immunotherapy based on genetic engineering of T lymphocytes.
Expression of CARs on T cells enables direct binding to target cell-specific surface antigens and circumvents the need for major histocompatibility complex-restricted antigen presentation.
Clinical translation of CAR-T therapy for respiratory diseases is impeded by limited tumor-specific antigens, heterogeneous target antigen expression, immunosuppressive solid-tumor microenvironments, and manufacturing and logistical hurdles.
Approval Evidence
1 source5 linked approval claimsfirst-pass slug car-t-therapy
Chimeric antigen receptor (CAR) T cell (CAR-T) therapy is a form of adoptive immunotherapy based on the genetic engineering of T lymphocytes.
Source:
application scopesupports
CAR-T therapy is being investigated for respiratory malignancies, severe asthma, infectious diseases, idiopathic pulmonary fibrosis, and autoimmune disorders with pulmonary involvement.
Source:
future potentialsupports
With ongoing advancements, CAR-T therapy holds promise as a versatile and effective treatment for otherwise refractory respiratory diseases.
Source:
mechanismsupports
CAR-T therapy is an adoptive immunotherapy based on genetic engineering of T lymphocytes.
Source:
mechanismsupports
Expression of CARs on T cells enables direct binding to target cell-specific surface antigens and circumvents the need for major histocompatibility complex-restricted antigen presentation.
Source:
translation barriersupports
Clinical translation of CAR-T therapy for respiratory diseases is impeded by limited tumor-specific antigens, heterogeneous target antigen expression, immunosuppressive solid-tumor microenvironments, and manufacturing and logistical hurdles.
Source:
Comparisons
Source-stated alternatives
No direct alternative therapeutic platform is named in the abstract. The review does mention emerging combinatorial strategies to improve efficacy and safety.
Source:
No direct alternative therapeutic platform is named in the abstract. The review does mention emerging combinatorial strategies to improve efficacy and safety.
Source-backed strengths
precise immune responses; efficient immune responses; potential versatility across multiple respiratory disease categories
Source:
precise immune responses
Source:
efficient immune responses
Source:
potential versatility across multiple respiratory disease categories
Compared with CAR-engineered macrophages
CAR-T therapy and CAR-engineered macrophages address a similar problem space because they share manufacturing, translation.
Shared frame: same top-level item type; shared target processes: manufacturing, translation; shared mechanisms: translation_control
Compared with fifth-generation CAR-T cells
CAR-T therapy and fifth-generation CAR-T cells address a similar problem space because they share manufacturing, translation.
Shared frame: same top-level item type; shared target processes: manufacturing, translation; shared mechanisms: translation_control
CAR-T therapy and T cells redirected for universal cytokine-mediated killing address a similar problem space because they share manufacturing, translation.
Shared frame: same top-level item type; shared target processes: manufacturing, translation; shared mechanisms: translation_control
Ranked Citations
- 1.